On October 11, 2017 Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, reported that the abstract featuring data from the Phase 1a/1b clinical trial evaluating the immunotherapy combination of its CSF-1R antibody, cabiralizumab (FPA008), with Opdivo (nivolumab), Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, has been selected for a late breaking oral presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 32nd Annual Meeting, being held Nov. 8-12, 2017 in National Harbor, Maryland (Press release, Five Prime Therapeutics, OCT 11, 2017, View Source [SID1234520858]).

Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Presentation
Session Name: Clinical Trials and Novel Combinations
Abstract Title: “First in Human Phase I Dose Escalation and Expansion of a novel combination, anti-CSF1-receptor (cabiralizumab) plus anti-PD-1 (nivolumab) in patients with advanced solid tumors.”
Session Date and Time: Saturday, Nov. 11, 2017, 3:30-6:00 PM EST
Presentation Time: 4:30-4:45 PM EST

This will be the first presentation of clinical data on a combination of a CSF-1R antibody and a checkpoint inhibitor, to the Company’s knowledge.

In the Phase 1a/1b trial, Five Prime and Bristol-Myers Squibb are evaluating the safety, tolerability and preliminary efficacy of the combination in advanced solid tumors. The presentation at the SITC (Free SITC Whitepaper) Annual Meeting will focus on preliminary safety, pharmacokinetic and pharmacodynamic data as well as initial efficacy data from one of the expansion cohorts.